Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states

View Full Paper
Ask AI
Bookmark
Share

Authors

LBLauren BanaszakSLSara E. LewisAFAlejandro Ferrer

Discussion

Loading...

Member takes

Overview

Clinical outcomes highlight hematologic malignancy in individuals with ANKRD26 pathogenic variants, suggesting implications for monitoring.

Key Points

  • This research aims to define the malignancy characteristics and clinical outcomes associated with ANKRD26-related thrombocytopenia.
  • Established an international cohort of individuals with ANKRD26-related thrombocytopenia
  • Collected clinical, pathological, and molecular data from 27 individuals across 11 institutions
  • Performed statistical analyses using R (v4.4.2)
  • 41% of patients developed hematologic malignancies, including chronic myeloid leukemia and myelodysplastic neoplasms
  • Mean pre-malignancy platelet count was 45 K/uL
  • 60% cumulative incidence of hematologic malignancy by age 80 years

Cite This Study

Banaszak et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4b6https://doi.org/10.1182/blood-2025-1440
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy2025
  2. 2Intermediate and high-risk clonal hematopoiesis in germline predisposition families2025
  3. 3Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p212026 · 1 citations
  4. 4Germline predisposition in pediatric malignancies: Insights from a retrospective study at Dana-Farber Cancer Institute2025
  5. 5Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults2025